Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    15322749 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial
Conditions: Impaired Glucose Tolerance;   Cardiovascular Disease;   Glucose Metabolism Disorders
Interventions: Drug: Ramipril;   Drug: Rosiglitazone

Indicates status has not been verified in more than two years